Ultragenyx Pharmaceutical Inc
F:UP0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Ultragenyx Pharmaceutical Inc
F:UP0
|
US |
|
Hanjaya Mandala Sampoerna Tbk PT
IDX:HMSP
|
ID |
|
Riverview Bancorp Inc
NASDAQ:RVSB
|
US |
|
P
|
PepsiCo Inc
XMUN:PEP
|
US |
|
P
|
Pernod Ricard SA
XBER:PER
|
FR |
|
H
|
Hess Corp
XBER:AHC
|
US |
|
T
|
Teck Resources Ltd
F:TEKB
|
CA |
|
H
|
Hanjaya Mandala Sampoerna Tbk PT
XMUN:HSZ
|
ID |
|
P
|
Prosus NV
JSE:PRX
|
NL |
|
Loomis AB
F:K900
|
SE |
|
H
|
Huntington Bancshares Inc
F:HU3
|
US |
|
P
|
PetroChina Co Ltd
F:PC6
|
CN |
|
Orthofix Medical Inc
F:OM2
|
US |
Wall St Price Targets
UP0 Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for UP0 is 61.39 EUR with a low forecast of 31.53 EUR and a high forecast of 116.54 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UP0's stock price target?
Price Target
61.39
EUR
According to Wall Street analysts, the average 1-year price target for UP0 is 61.39 EUR with a low forecast of 31.53 EUR and a high forecast of 116.54 EUR.
What is the Revenue forecast for Ultragenyx Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Revenue over the next 8 years is 23%.
What is the Gross Profit forecast for Ultragenyx Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Gross Profit over the next 7 years is 23%.
